Recently, the Shanghai Municipal Science and Technology Commission issued the "Announcement on the Third Batch of High-tech Small and Medium-sized Enterprises Included in the 2026 List in Shanghai." Atheron Therapeutics was successfully included in this batch and has officially received the SME designation.
The evaluation system is administered by the Ministry of Industry and Information Technology and the Ministry of Science and Technology. This designation represents a national-level recognition of an enterprise's technological innovation capabilities. To qualify, companies must meet strict criteria, including the ratio of R&D staff, R&D investment, and intellectual property outcomes. This successful inclusion affirms the authorities' confidence in Atheron Therapeutics' R&D and innovation capabilities.
Looking ahead, Atheron Therapeutics will take this opportunity to further increase its R&D investment, accelerate its product pipeline, strengthen its innovation capacity, and contribute to advancements in pharmaceutical technology.
Reference Links
Announcement of the Shanghai Municipal Science and Technology Commission: Announcement on the Third Batch of Technology-Oriented Small and Medium-sized Enterprises Included in the 2026 List in Shanghai (in Chinese)
https://stcsm.sh.gov.cn/zwgk/tzgs/gsgg/zhgsgg/20260819/e216213fc95b4af5bb2458422dca41af.html